it increased from a baseline median of 56 M (IQR: 27101) to 123 M (IQR: 42135) after 24 h
[1] The medication also slows gastric emptying, which contributes to prolonged feelings of fullness after meals and helps regulate postprandial glucose excursions
BPC-157's NGF upregulation in enteric neurons could theoretically restore normal vagal signalling over time, which is why gastric emptying improvements in animal studies persist beyond the peptide's plasma half-life (approximately 4 hours subcutaneously)
It is used to boost immunity, improve skin, and support metabolism
However, these inconsistencies may be due to variations in disease chronicity, age, and symptom severity among study participants
Tirzepatide (dual GLP-1/GIP receptor agonist) shows numerically higher weight loss in trials (~21% vs ~15% for semaglutide over 68 weeks), but real-world response varies